MACULAR DEGENERATION TREATMENT MARKET ANALYSIS

Market Challenges And Opportunities

• Lack of awareness regarding macular degeneration
• Increasing usage of off-label medications

Market Drivers:

1. Increasing burden of retinal disorders worldwide is expected to propel growth of the global macular degeneration treatment market over the forecast period. For instance, retinal disorders have emerged as potential threats in both developed and developing countries. The prevalence retinal disorders is increasing, and as a result, vision loss is becoming a major public health concern. According to the BrightFocus Foundation (brightfocus.org), around 11 million people in the United States have some form of age-related macular degeneration, and this number is expected to reach around 22 million by 2050.
2. Growing geriatric population across the globe is expected to boost the growth of the global macular degeneration treatment market during the forecast period. Retinal disorders increased with ageing. AMD is the most common cause of blindness prevalent in developed countries, particularly in people older than 60 years. According to the World Health Organization (WHO), in 2019, the number of people aged 60 years and older was 1 billion. This number is expected to reach around 1.4 billion by 2030 and 2.1 billion by 2050.

Market Opportunities:

1. Increasing demand for safe and effective treatment is expected to provide significant growth opportunities for players in the global macular degeneration treatment market. For instance, Age-related macular degeneration is prevalent and debilitating disease with the rise in demand for treatment. There is no cure, but treatment may slow the disease and keep people from vision loss. In May 2022, Chugai Pharmaceutical Co., Ltd. launched Vabysmo Intravitreal Injection 120 mg/mL for the treatment of AMD associated with subfoveal choroidal neovascularization and diabetic macular edema (DME).
2. Rise in awareness among people about macular degeneration is expected to offer lucrative growth opportunities for players in the macular degeneration treatment market. For instance, AMD is a major cause of irreversible blindness, and awareness regarding AMD is important to prevent a blindness. Large-scale campaigns & programs are essential to raise awareness among people regarding AMD. The National Eye Health Education Program (NEHEP) is dedicated to raising awareness, especially in February, about vision and aging.